| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5d757248068d9a3ff194b3c4378a695b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1dd4da6856964b12bd92c2670aa9d9fd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_09a5dfab65d57500bec3a5cfe221539a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9e0f4b5b34073df5d76cb72d811ca50e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a66b8bfd52c589626211273cbb371076 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-752
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-899
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0065
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1611
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1664 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-00 |
| filingDate |
2014-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99c3b969dbbd96b33ff12608a72d5b92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af581ebb0ae6842ece1b6a73849bb31c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_255b3bde139d92ed42be869f582edfd0 |
| publicationDate |
2016-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2016108774-A1 |
| titleOfInvention |
Essential oil loaded mucoadhesive nanocomposite delivery system for gastrointestinal system |
| abstract |
Current treatments for H. pylori infection are not efficient enough due to poor diffusion of antibiotics to mucus layer, low stability, side effects and insufficient residence time of antibiotics in gut, antibiotic resistance of H. pylori and allergy of patients against antibiotics. Therefore, alternative therapies including new drugs and therapeutic approaches with enhanced action and reduced side effects are needed to achieve high eradication rate of the bacteria. This invention is related with eradication and/or prevention therapy of H.pylori that provides better diffusion to mucus layer and stabilization in gastric conditions. This invention comprises the local treatment of H.pylori and/or improving the drug release profiles of encapsulated essential oil within chitosan/nanoclay microspheres which could be located in gastrointestinal system. Therefore, the aim of this invention is to encapsulate essential oil in gastroretentive chitosan/nanoclay spheres which has antimicrobial activity against H.pylori and release in a controlled manner in the prior to art. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109464422-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3886884-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109464422-B |
| priorityDate |
2014-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |